Dianthus Therapeutics (DNTH) Operating Income (2017 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Operating Income of -$40.3 million for Q3 2025, down 34.74% year-over-year from -$61.7 million in Q3 2024, and down 15.35% quarter-over-quarter from -$34.9 million in Q2 2025.
Dianthus Therapeutics (DNTH) Operating Income (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Operating Income history runs 9 years deep, the most recent figure standing at -$40.3 million for Q3 2025.
- In Q3 2025, Operating Income fell 34.74% year-over-year to -$40.3 million; the TTM figure through Sep 2025 stood at -$140.3 million (down 69.24% YoY), while the FY2024 annual figure was -$101.9 million, down 111.45% from the prior year.
- Operating Income for Q3 2025 stood at -$40.3 million, down from -$34.9 million in the prior quarter.
- The five-year high for Operating Income was -$7.7 million in Q1 2023, with the low at -$40.3 million in Q3 2025.
- The 5-year median for Operating Income is -$18.2 million (2021), against an average of -$20.7 million.
- The sharpest annual moves came in 2023 and 2024: Operating Income soared 67.76% in 2023, then plunged 146.34% in 2024.
- Dianthus Therapeutics' Operating Income stood at -$20.1 million in 2021, then surged by 46.91% to -$10.7 million in 2022, then fell by 21.16% to -$13.0 million in 2023, then slumped by 146.34% to -$31.9 million in 2024, then slipped by 26.23% to -$40.3 million in 2025.
- Business Quant data shows DNTH's Operating Income at -$40.3 million in Q3 2025, -$34.9 million in Q2 2025, and -$33.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -40.29 Mn |
| Jun 30, 2025 | -34.93 Mn |
| Mar 31, 2025 | -33.18 Mn |
| Dec 31, 2024 | -31.92 Mn |
| Sep 30, 2024 | -29.90 Mn |
| Jun 30, 2024 | -22.20 Mn |
| Mar 31, 2024 | -17.84 Mn |
| Dec 31, 2023 | -12.96 Mn |
| Sep 30, 2023 | -15.76 Mn |
| Jun 30, 2023 | -11.78 Mn |
| Mar 31, 2023 | -7.68 Mn |
| Dec 31, 2022 | -10.69 Mn |
| Sep 30, 2022 | -8.25 Mn |
| Jun 30, 2022 | -18.08 Mn |
| Mar 31, 2022 | -23.83 Mn |
| Dec 31, 2021 | -20.14 Mn |
| Sep 30, 2021 | -18.25 Mn |
| Jun 30, 2021 | -17.61 Mn |
| Mar 31, 2021 | -18.70 Mn |
| Dec 31, 2020 | -19.07 Mn |